The V₂ receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells

G. Marroncini¹,² · C. Anceschi¹,² · L. Naldi¹,² · B. Fibbi¹,² · F. Baldanzi² · M. Maggi² · A. Peri¹,²

Abstract

Purpose Hyponatremia, the most frequent electrolyte alteration in clinical practice, has been associated with a worse prognosis in cancer patients. On the other hand, a better outcome has been related to serum sodium normalization. In vitro studies have shown that low extracellular sodium promotes cancer cells proliferation and invasiveness. Tolvaptan, a selective vasopressin receptor type 2 (V₂) antagonist, has been effectively used in the last decade for the treatment of hyponatremia secondary to the Syndrome of Inappropriate Antidiuresis. A few in vitro data suggested a direct role of tolvaptan in counteracting cancer progression, so far. The aim of this study was to evaluate the effect and the mechanism of action of tolvaptan in cell lines from different tumours [i.e. colon cancer (HCT-8), hepatocarcinoma (HepG2), neuroblastoma (SK-N-AS)].

Methods and results First, we showed that these cell lines express the V₂ receptor. Tolvaptan significantly reduced cell proliferation with an IC₅₀ in the micromolar range. Accordingly, reduced levels of cAMP, of the catalytic α subunit of PKA, and a reduced pAKT/AKT ratio were observed. Tolvaptan effectively inhibited cell cycle progression, whereas it induced apoptosis. Furthermore, it reduced cell invasiveness. In particular, anchorage-independent growth and the activity of collagenases type IV were blunted in the three cell lines. Accordingly, tolvaptan counteracted the RhoA/ROCK1–2 pathway, which has a pivotal role in regulating cell movement.

Conclusions Overall, these findings indicate that tolvaptan effectively inhibits tumour progression in vitro. Further studies should clarify whether the V₂ receptor might be considered a possible target in anti-cancer strategies in the future.

Keywords Tolvaptan · AVP receptors · Hyponatremia · Cancer · SIAD

Introduction

Hyponatraemia is the most frequent electrolyte imbalance in cancer and it occurs in up to 40% of patients at the time of hospital admission [1, 2].

The syndrome of inappropriate antidiuresis (SIAD) is the most frequent cause of hyponatremia in cancer patients [3]. In addition to ectopic vasopressin (AVP) secretion by tumoural cells, particularly in lung cancer [4], other factors may cause SIAD in this setting as follows: several anticancer drugs, including chemotherapeutic agents, molecular targeted agents and immune checkpoint inhibitors, palliative treatments (e.g. opioids), nausea, and pain. Intravenous hydration during chemotherapy or comorbidities associated with hyponatremia (e.g. heart failure, renal failure, liver cirrhosis) may also facilitate serum sodium concentration ([Na⁺]) reduction [4–7].

It is now well known that hyponatremia represents a negative prognostic factor among cancer patients. Indeed, low [Na⁺] has been associated with a significantly decreased progression-free and overall survival in patients with tumours of different organs [1, 8–18]. Furthermore, hyponatremia has been related to increased length of hospital stay and health costs [8, 19–22]. Interestingly, it has been shown that [Na⁺] correction is associated with a reduced mortality [9, 23, 24]. As a matter of fact, serum [Na⁺] has been proposed as a possible biomarker to identify high-risk cancer patients [25].
A crucial question is whether hyponatraemia is a surrogate marker of disease severity or a factor that directly contributes to cancer progression [26]. Admittedly, a clear-cut answer to this question does not exist, yet. However, we have recently demonstrated that low extracellular [Na+] promotes cell proliferation, invasion and tumourigenicity in vitro, in different cancer cell lines [i.e., pancreatic adenocarcinoma (PANC-1), neuroblastoma (SK-N-AS, SH-SY5Y), colorectal adenocarcinoma (HCT-8), chronic myeloid leukemia (K562) cells] [27].

The past decade has seen the introduction of a new class of drugs, namely vaptans, which are non-peptide vasopressin receptors antagonists. In particular, a selective antagonist of the AVP receptor type 2 (V2), namely tolvaptan, has been approved in 2009 in the U.S. and in Europe for the treatment of adult patients with hyponatremia secondary to SIAD. Tolvaptan induces water diuresis and has been shown to effectively correct hyponatremia in different clinical settings, including cancer patients [28–33]. In view of the aforementioned beneficial effects of the correction of hyponatremia in cancer patients, it is conceivable that tolvaptan may have a favourable effect, too.

In addition, it has to be considered that tolvaptan has been subsequently approved also for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Here, tolvaptan is able to reduce renal cyst growths and the rate of estimated glomerular filtration decrease [34, 35]. This unpredicted effect has been related to its inhibitory effect on intracellular cAMP production in kidney epithelial cells [36]. Noteworthy, in vitro studies have shown that tolvaptan reduces proliferation and invasion in hepatocarcinoma and renal carcinoma cells [37, 38]. Furthermore, very recently we have demonstrated that in small-cell lung cancer cells tolvaptan counteracts cell proliferation and invasivity, yet triggers apoptosis, mainly via the inhibition of the RhoA/ROCK pathway [39].

The aim of the present study was to investigate on the effects and the mechanism of action of tolvaptan in different cell lines from colon cancer, hepatocarcinoma and neuroblastoma.

Materials and methods

Cell cultures

Hepatocellular carcinoma (HepG2) (HB-8065, RRID:CVCL_0027), stromal (S)-type (SK-N-AS) neuroblastoma (CRL-2137, RRID:CVCL_1700), and colon carcinoma (HCT-8) (CCL-244, RRID:CVCL_2514) human cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). Stock cell lines were routinely cultured in Dulbecco’s modified Eagle medium or RPMI-1640 supplemented with 10% fetal bovine serum (FBS), L-glutamine and antibiotics (50 U/mL penicillin and 50 μg/mL streptomycin) and maintained at 37 °C in a humidified atmosphere (5% CO2/95% air). All the reagents for cell culture were purchased from Sigma Chemical Co. (St. Louis, MO, USA). To analyse the effects of tolvaptan, cells were cultured in DMEM or RPMI medium for 48 h before experiments were performed, as previously described [39].

Immunofluorescence

Cells were fixed in 4% paraformaldehyde, blocked in PBS/0.1% BSA/0.05% Tween for 1 h, and then incubated with anti-rabbit polyclonal AVPR2 antibody (PA5-75,409, RRID:AB_2719137, Thermo Fisher Scientific, Walthan, MA, USA) (1:100 dilution) and Hoescht 333,342 (NucBlue Live cell Stain Ready Probes reagent, R37605, Life Technologies, Carlsbad, CA, USA) overnight. The day after, cells were washed twice in PBS and stained with anti-Rabbit IgG Alexa Fluor488 secondary antibody for 1 h at room temperature in the dark. Finally, cells were washed and mounted in fluorescent Prolong Gold Antifade medium (P36930, Life Technologies, Carlsbad, CA, USA) for observation under an inverted fluorescence microscope (Leica Biosystems, Milan, Italy) equipped with a camera.

Analysis of cell proliferation and viability

After 48 h of tolvaptan treatment, tumour cells were harvested by trypsinization and counted twice using a hemocytometer. Cell viability and proliferation were assessed using Cell Counting Kit-8 (Dojindo Molecular Technologies, Rockville, USA). 10.000 cells/well were seeded in 96-well plates and treated with WST-8, which is directly reduced by intracellular dehydrogenases. Once metabolized, WST-8 creates a coloured product (formazan), directly proportional to the number of metabolic and proliferative cells present in wells. The experiments were run according to manufacturer’s protocol, and luminescence (450 nm and 570 nm filter respectively) was recorded with a Wallac multplate reader (Perkin-Elmer, Monza, Italy). The results were expressed as optical density OD/well (\(\text{mean} \pm \text{SE}\)) normalized versus control. The experiments were performed in 8-wells/sample and at least two times.

Western blot analysis

Cells were lysed in RIPA lysis buffer supplemented with complete protease and phosphatase inhibitor cocktail, and the protein concentrations were determined using a Bradford protein assay. Cell lysates (20–40 μg of proteins) were fractionated by 12% Mini-PROTEAN TGX Stain-Free Precast Gels (Biorad, Hercules, CA, USA) and transferred
Enzyme-linked immunosorbent assay (ELISA)

The intracellular cAMP concentration was measured with the competitive cAMP ELISA Kit (#4339, Cyclic AMP XP® Assay Kit, Cell Signalling Technology) according to the manufacturer’s protocol. HCT-8, HepG2 and SK-N-AS cells were cultured in 6-well plates and treated with 30, 50 and 70 μM of tolvaptan (HCT-8 and HepG2) or with 20, 40 and 50 μM of tolvaptan (SK-N-AS). Then, 2.5 × 10^4 cells for HCT-8 and 5 × 10^4 cells for HepG2 and SK-NA-S were plated into a 96-well plate. After 24 h, cells were incubated in serum-free medium and subsequently lysed on ice with 100 μl of lysis buffer for 5–10 min and centrifuged at 12,000 rpm for 10 min. Afterwards, the HRP-linked cAMP solution and 1:1 volume of sample was added to the cAMP assay plate and incubated for 3 h. After being washed four times with Wash Buffer 1X, the substrate was added to the assay plate and incubated for 30 min. Following the addition of the stop solution, the absorbance was detected at 450 nm using a microplate reader and the concentration of cAMP was calculated according to a standard curve.

Immunocytochemistry

HCT-8, SK-N-AS and HepG2 cells were seamed on a glass slide. One day after, tolvaptan was added to the medium and incubated for 48 h before proceeding with the immunostaining, which involves fixation, permeabilization, and antibody incubation. Indeed, cells were first fixed with 4% neutral buffered formalin for 20 min, washed twice in PBS 1X and permeabilized with 0.05% of Triton X-100 for 1 h at room temperature. Afterwards, glass slides were incubated with anti-Cleaved caspase-3 (Asp175) primary antibody (9661, RRID:AB_2341188, Cell Signaling Technology, Danvers, MA, USA) (1:100 dilution) overnight at 4 °C, and subsequently with anti-rabbit IgG HRP conjugated (7074, RRID:AB_2099233, Cell Signaling Technology, Danvers, MA, USA). Protein were detected using AEC (3-amino-9-ethylcarbazole) Substrate Peroxidase (HRP) Kit, (SK-4200, Vector Laboratories, Burlingame, CA, USA) that create a red precipitate in presence of caspase-3 protein. Slides were counterstained with Gill’s haematoxylin n°3 (05-06015E, Bio Optica Milano Spa, Milan, Italy) and the staining effect was observed and photographed under a microscope. Both control and tolvaptan-treated cells were examined: five fields per slide were randomly chosen under light microscopy at high-power field (× 40) and caspase-3 positive cells have been counted.

Cell cycle and annexin V/PI analyses

HCT-8, SK-N-AS and HepG2 cells were incubated with tolvaptan for 48 h, harvested and washed twice with sterile PBS to perform cytofluorimetric analysis of cell cycle and annexin V/PI using the Guava® Muse® Cell Analyzer (Luminex Corporation, Austin, TX, USA). As previously described, cells must be fixed using 70% ethanol and stored at -20 °C for at least 3 h. After fixing and washing, 1 × 10^6 and 25 × 10^4 cells were stained with 200 μl and 100 μl of Muse™ Cell Cycle and Annexin V & Dead Cell Reagent (Luminex Corporation, Austin, TX, USA) respectively, and incubated for 30 min at room temperature before performing cytofluorimetric analysis. Results of cell cycle were expressed as % of cells in G0/G1, S and G2/ M phases; results of annexin V/PI were expressed as % of live and total apoptotic cells normalized versus stain free acquisition.

Invasion analysis and ECM degradation

Invasive migration capacity of cancer cell lines was assessed by a standard Transwell invasion system and by zymography assay. First, 1 × 10^6 tolvaptan pre-treated tumour cells were induced to migrate under chemoattractant stimuli (FBS serum), using polycarbonate filter inserts (8 μm) (Corning, New York, USA) precoated with 0.3% BD Matrigel.
Basement Membrane (BD Becton, Dickinson and Company, New Jersey, USA). Finally, 24 h after the induction at 37 °C, invasive cells were stained with 0.1% crystal violet/methanol and observed under the microscope. To obtain a quantitative analysis of migrated cells, the inserts were decoloured with dimethyl sulfoxide (DMSO) and the dye mixture was measured by spectrophotometer (Perkin-Elmer, Monza, Italy) at the optical density (OD) of 560 nm.

After 48 h of tolvaptan exposition, cancer cells supernatant was collected to perform zymography and analysis of type IV collagenases (MMPs) secretion. Samples were separated with Protean II system (Bio-Rad, Hercules, CA, USA), in SDS-PAGE Tris–glycine 8.0% polyacrylamide gel containing 2 mg/ml of gelatine at a constant current of 90 mV. After run, gels were washed twice in 2.5% Triton X-100 for 15 min and incubated in a rocking platform with reaction buffer (50 mM Tris–HCl, pH 7.5, 5 mM CaCl2, 200 mM NaCl and 1% Triton X-100) overnight at 37 °C. The day after, gels were stained with 0.1% Coomassie blue R-250 (Amersham Pharmacia Biotech, Milan, Italy) for at least 1 h in 40% 2-propanol. White bands corresponding to MMP2 and MMP9 were quantified as % of pixels normalized versus untreated cells.

Soft agar assay

Soft agar assay was used in order to analyse the effect of tolvaptan on anchorage independent growth of tumour cells by preparing a multilayer plate, as previously described [27]. 5 × 10⁴ cells in RPMI 1640 double added with FBS were plated in the upper layer (0.3% of noble agar) together with three different concentrations of tolvaptan (3 wells per group). Cells were maintained at a condition of 37 °C and 5% CO₂ for 21 days; finally, the number of colonies in each well was counted by using a light microscope after staining with 0.1% crystal violet solution.

RNA extraction, reverse transcription and qPCR

Total RNA was extracted by using Tri Reagent with DNAse treatment, according to the manufacturer’s instruction, and samples were quantified spectrophotometrically. After reverse transcription (Taqman Reverse Transcription Reagents, Applied Biosystem Inc., Foster City, CA, USA), cDNA was amplified using a Termocycler (Perkin-Elmer Cetus, Norwalk, CT, USA) through three steps (35 cycles): 94 °C for 45 s, 60 °C for 45 s, 72 °C for 60 s. The expression of target genes was quantitatively analysed by real-time RT-PCR using Pre-developed TaqMan® Assays. The probes were Assay-On-Demand products (Applied Biosystem Inc., Foster City, CA, USA) for ROCK-1 (Hs 00178463_m1), ROCK-2 (Hs00153074_m1) and RHOA, (Hs00357608_m1). The mRNA quantitation was based on the comparative Ct (for cycle threshold) method and normalized to 18S RNA (Hs03003631_g1). Results were expressed as ΔΔct normalized versus control sample. All measurements were carried out in triplicate and at least two independent experiments were performed.

Statistical analysis

All statistical analyses were carried out with the use of SPSS software Version 13.0 (SPSS, Chicago, IL, USA). Data were expressed as the mean ± standard error from at least three separate experiments. Statistical significance of the results was analysed by paired t-test, and P < 0.05 was considered to be statistically significant.

Results

Cell proliferation

First, the expression of the V₂ receptor in cell lines was assessed. Western blot analysis confirmed that the receptor was expressed in HCT-8, HepG2 and SK-N-AS cells (Fig. 1A). Immunofluorescence indicated the membrane localization of the receptor (Fig. 1B). We found that tolvaptan dose-dependently reduced the rate of cell proliferation of HCT-8, HepG2 and SK-NAS cells, with an IC50 of 52 µM, 38 µM and 40 µM, respectively, after a 48 h exposure (Fig. 2A–B). Interestingly, the inhibitory effect of tolvaptan on cell proliferation was progressively reduced when cells were exposed to low [Na⁺] and it was completely blunted at the lowest [Na⁺] (90 mM) in all cell lines (Fig. 2C).

PKA is the first key regulator of the V₂ receptor signalling pathway. Therefore, the effect of tolvaptan on cAMP levels was determined and was found to be reduced in all cell lines (Fig. 3A). Accordingly, the expression of the catalytic α subunit of PKA was reduced in cells exposed to tolvaptan. (Fig. 3B). The PI3K/AKT pathway was also investigated, and a reduced pAKT/AKT ratio was observed upon tolvaptan treatment (Fig. 3C).

Cell cycle and apoptosis

The effect of tolvaptan on cell cycle progression was analyzed. The number of cells in G0/G1 dose-dependently decreased upon the exposure to increasing concentrations of the drug, in all cell lines tested. Similarly, tolvaptan induced a decrease in the number of cells in S phase, whereas cells in G2-M appeared increased (Fig. 4).

With regard to apoptosis, the exposure to the V₂ receptor antagonist was associated with an increase in the percentage of apoptotic cells in HCT-8, HepG2 and SK-N-AS
cells, together with a decrease of live cells (Fig. 5A). This finding was paralleled by an increased immunostaining for caspase-3 (Fig. 5B).

**Anchorage-independent growth and invasivity**

The ability to grow in the absence of a solid substrate is a well-known feature of cancer cells in vitro. HCT-8, HepG2 and SK-N-AS cells proliferate and form colonies in soft agar [27, 40]. We demonstrated that the exposure to tolvaptan effectively reduced the number of cell colonies able to grow in soft agar (Fig. 6).

In contrast with the observation that the invasiveness of cancer cells is amplified in low extracellular [Na⁺] [27, 39], and in agreement with previous observations in small cell lung cancer H69 cells [39], tolvaptan blunted the ability of HCT-8, HepG2 and SK-N-AS cells to cross matrigel-coated membranes (Fig. 7A).

Zymography assays indicated that impaired cell invasiveness induced by tolvaptan was associated with the reduction of type IV collagenases activity (MMP2 and MMP9) (Fig. 7B).
Fig. 2  Effect of tolvaptan on HCT8, HepG2 and SK-N-AS cell proliferation.  

A–B Dose–response curve of the effect of tolvaptan on proliferation, as assessed by WST-8 assay and identification of the IC50 dose. Results are expressed as number of cells ± SE normalized vs 0 µM tolvaptan (n = 3) (*p ≤ 0.02). Images are representative of cells growth.  

C Effect of tolvaptan on cell proliferation at different [Na+], as assessed by WST-8. Results are expressed as number of cells ± SE normalized vs 153 mM [Na+] (n = 3) (*p ≤ 0.05) and vs 0 µM tolvaptan (considered as 1) (n = 3) ($p ≤ 0.05$)
The RhoA/ROCK1-2 pathway has an important role in the regulation of cell movement via the remodeling of actin cytoskeleton. Previous evidence indicated that low extracellular [Na\(^+\)] activates this pathway \[27, 39\]. In addition, we have shown that tolvaptan has an inhibitory effect in H69 cells \[39\].

Here, we found that tolvaptan reduced the mRNA amount of RhoA, ROCK1, ROCK2 in HCT-8, HepG2 and SK-N-AS.

**Fig. 3** Effect of tolvaptan on cAMP, PKA and AKT/pAKT. Elisa assay of cAMP levels (A), and Western Blot analysis of PKA (B), AKT and Ser473-phosphorylated AKT (pAKT) (C). Images are representative of three different experiments, and graphs show cAMP, PKA and pAKT pixels /AKT pixels normalized vs 0 µM tolvaptan (*p ≤ 0.05).

**RhoA/ROCK1-2 pathway**

The RhoA/ROCK1-2 pathway has an important role in the regulation of cell movement via the remodeling of actin cytoskeleton. Previous evidence indicated that low extracellular [Na\(^+\)] activates this pathway \[27, 39\]. In addition, we have shown that tolvaptan has an inhibitory effect in H69 cells \[39\].

Here, we found that tolvaptan reduced the mRNA amount of RhoA, ROCK1, ROCK2 in HCT-8, HepG2 and SK-N-AS.
1700 Journal of Endocrinological Investigation (2022) 45:1693–1708

cells (Fig. 8). These data were confirmed by the analysis of protein expression by Western blot analysis, (Fig. 9A and B). Overall, the degree of the inhibitory effect of different concentrations of tolvaptan on RhoA/ROCK1-2 expression varied in the different cell lines and significant differences were more often observed in HCT-8 cells. The downstream effect of the inhibition of the RhoA/ROCK1-2 pathway was confirmed by the reduced cofilin/P cofilin ratio upon tolvaptan exposure (Fig. 9C), similarly to what had been previously observed in H69 cells [39].

Discussion

In recent years it became clear that hyponatremia may have a negative impact on the prognosis of cancer patients. Recent evidence indicated that the V2 receptor antagonist tolvaptan has antiproliferative effects in vitro in cells from kidney, liver and small-cell lung cancer [37–39].

In this study, we evaluated the effect of tolvaptan in different cell lines from colon cancer (HCT-8), hepatocarcinoma (HepG2) and neuroblastoma (SK-N-AS). No previous study had assessed the effect of this molecule in colon cancer or in neuroblastoma. HepG2 cells had been used in a previous study [37] and have been added here in order to have a validated control. In addition, hyponatremia likely due to ectopic AVP secretion has been described, yet rarely, in colon cancer [41], hepatocarcinoma [42] and neuroblastoma [43].

First, we assessed the presence of the V2 receptor in the selected cell lines. This receptor is normally located on the basolateral surface of the cells of renal collecting tubules and it is activated by AVP binding, which leads to cAMP generation, PKA activation and then to the synthesis and activation of the aquaporin 2 water channel [29]. We found that the three cancer cell lines express the V2 receptor, which is located in the cell membrane. Tolvaptan effectively inhibited cell proliferation with IC50 in the micromolar range, similarly to data previously reported in the literature [37–39]. In particular, the IC50 for HCT-8 cells was 52 µM, for HepG2 38 µM and for SK-N-AS 40 µM. Accordingly, the amount of cAMP and the expression of the catalytic α subunit of PKA appeared to be reduced upon tolvaptan treatment, as well as the pAKT/AKT ratio, in all the three cell lines.

Interestingly, the anti-proliferative effect of tolvaptan was markedly reduced, yet not abolished, with the exclusion of the lowest [Na+] (i.e. 90 mM), in cells exposed to low [Na+].

Fig. 4 Effect of tolvaptan on cell cycle progression. Cytomfluorimetric analysis of cell cycle; plots are representative of cell cycle trend and indicate % of G0/G1, S and G2/M cells. Graphs show the results from three experiments and are expressed as % of cells (mean ± SE), normalized vs 0 µM tolvaptan. (# = G0/G1 p ≤ 0.05 vs 0 µM; * = S p ≤ 0.05 vs 0 µM; § = G2/M p ≤ 0.05 vs 0 µM)
Fig. 5 Effect of tolvaptan on cell death. The effects of tolvaptan on apoptosis were assessed by cytofluorimetry and results are expressed as mean ± SE of the % of live and dead cells from three different experiments (# = apoptotic cells p ≤ 0.05 vs 0 µM; * = live cells p ≤ 0.05 vs 0 µM) (A). Immunocytochemistry of caspase-3 on cancer cells at increasing doses of tolvaptan. Tot apoptotic = total apoptotic cells (early and late) (B); images are representative of two different experiments, and graphs show the % of positive cells normalized vs 0 µM tolvaptan (*p ≤ 0.05)
This result is in keeping with previous experimental data that showed that low [Na+] promotes tumoural cell proliferation, including HCT-8 and SK-N-AS cells, that were included in the present study [27, 39].

Then, we analyzed the effect of tolvaptan on cell cycle progression. The number of G0-G1 and S cells decreased upon tolvaptan exposure in all the three cell lines, whereas cells in G2-M appeared increased. These findings are in keeping with similar published observations [37, 38] and suggest that tolvaptan prevents cell cycle progression toward cell division.

On the other hand, when we analyzed the effect of tolvaptan on apoptosis by citofluorimetry, we observed a significantly increased number of apoptotic cells at all the drug concentrations that were used and in all cell lines. Accordingly, the number of live cells decreased. In agreement with these data, we also found that the amount of expression of caspase-3, a key modulator of apoptosis, increased upon tolvaptan exposure. The effect of tolvaptan in promoting apoptosis observed here is in agreement with previous findings in small cell lung cancer cells [39], and confirm the data obtained in HepG2 cells [37].

It is known that growth in the absence of a solid support is a feature of malignant cells, and this has been shown previously in HCT-8, HepG2 and SK-N-AS cells [27, 40], in which low [Na+] was associated with an increased number of colonies. Here, we demonstrated that tolvaptan effectively reduced the ability of these cells to form colonies, when grown in soft agar, similarly to our previous results in small cell lung cancer cells [39].

Finally, we observed that the invasiveness of these cells was also counteracted by tolvaptan, and that this effect was associated with a reduced activity of type IV collagenases. In agreement with this finding, we observed that the RhoA/ROCK1-2 pathway was inhibited. This pathway is involved in the regulation of cytoskeleton dynamics, and thus in cell movement. In cancer, it has an important role in the induction of the metastatic cascade [44]. Interestingly, high levels of ROCK1 expression have been associated with a worse prognosis in several tumours, such
as neuroblastoma, bladder, laryngeal and breast cancer [45–48]. RhoA overexpression has been associated with a significantly reduced disease-free and distant metastasis-free survival in cervical squamous cell carcinoma [49]. A facilitative role for RhoA in inducing a more aggressive phenotype has been observed also in other malignancies, such as for instance lung adenocarcinoma [50], ovarian carcinoma [51] and lymphoma [52].

Fig. 7 Effect of tolvaptan on invasion. Cell invasion was analyzed through matrigel-coated invasion chambers; images are representative of invading cells after crystal violet stain, and graphs show the median value from three different experiments normalized vs 0 µM tolvaptan (*p ≤ 0.05) (A). The zymography assay was used to analyze the type IV collagenases activity (MMP2 and MMP9) by tumour cells after tolvaptan treatment. Images are representative of the areas of gels degradation by metalloproteinases, and bars represent the mathematical ratio of pixels from three experiments normalized vs 0 µM tolvaptan (*p ≤ 0.05) (B).
Accordingly, the RhoA/ROCK1-2 pathway has been suggested as a possible therapeutic target in cancer [45, 53, 54].

With regard to the downstream effector cofilin, we observed that tolvaptan determined a reduced cofilin/P-cofilin ratio in all the three cell lines. Cofilin depolymerizes F-actin and creates new actin monomers for polymerization, thus accelerating actin turnover and modulating cell movement. Upon phosphorylation, cofilin is inactivated [55, 56].

Overall, these findings add new evidence to the few data reported in the literature, so far, in favour of an antitumoural effect of the V2 receptor antagonist tolvaptan. Noticeably, the serum peak concentration of tolvaptan after a single dose of 30 mg in healthy volunteers is in the low micromolar range [57]. In ADPKD the daily regimen of tolvaptan may reach 120 mg [58]. These concentrations are very similar to those that effectively inhibited cell proliferation and invasion in vitro in our experimental models.

Vaptans have opened a new era in the treatment of hyponatremia secondary to SIAD and have been the first non-peptide molecules that targeted AVP receptors [29]. As already mentioned, in the past decade it became evident that hyponatremia negatively affects the course of different pathologies, including cancer. Remarkably, [Na+] correction has a favourable effect on patients’ outcome [23, 59–61]. However, vaptans appear to have an additional and direct antitumoural effect, which recalls their mode of action in reducing the growth of cysts in ADPKD [36, 62, 63]. AVP receptors are expressed in different cancer types, including breast, pancreatic, colorectal, gastrointestinal cancer, and small cell lung carcinoma [64, 65]. V1 receptor activation has been associated with increased cell growth [66, 67], whereas a more controversial role has been associated with the V2 receptor. Nevertheless, a proliferative effect related to V2 receptor activation has been observed in renal carcinoma cells [68]. The recent findings on the antitumoural effects of tolvaptan, a selective V2 receptor antagonist [39, 69, 70], in addition to the data shown in the present study, suggest that the V2 receptor can be considered a possible target against cancer. This hypothesis needs to be further confirmed in in vivo studies. With regard to this point, one study has

Fig. 8 Tolvaptan regulation of RhoA, ROCK1 and ROCK2 mRNA. Real Time qPCR analysis of the amount of RhoA, ROCK1 and ROCK1 mRNA upon tolvaptan exposure. Results are expressed as ΔΔct normalized vs 18S, used as the housekeeping gene. Bars represent the mean ± SE from three different experiments, normalized vs 0 µM tolvaptan (*p ≤ 0.05)
Fig. 9  Tolvaptan regulation of RhoA/ROCK1-2 pathway. RhoA (A), ROCK1 (B), and cofilin/P-cofilin (Ser3) (C) protein expression were analyzed by Western blot and images show representative gels from three different experiments. The plots represent the ratio between protein/stain free pixels and results are expressed as mean ± SE normalized vs 0 µM tolvaptan. (*p ≤ 0.05)
demonstrated that tolvaptan reduced cell proliferation and angiogenesis, while increasing apoptosis, in a mouse xenograft model of renal cancer [38].

Acknowledgements This research was supported by grants from Otsuka Pharmaceutical Europe Ltd. and PRIN 2017R5ZE2C.

Funding Open access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement.

Declarations

Conflict of interest The authors declare that they do not have any financial or non-financial interest that are directly or indirectly related to this work.

Ethical statement MM is a member of the Editorial Board of the Journal of Endocrinological Investigation.

Informed consent For this type of study formal consent is not required.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Doshi SM, Shah P, Lei X et al (2012) Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis Off J Natl Kidney Found 59:222–228. https://doi.org/10.1053/j.ajkd.2011.08.029
2. Berardi R, Rinaldi S, Caramanti M et al (2016) Hyponatremia in cancer patients: Time for a new approach. Crit Rev Oncol Hematol 102:15–25. https://doi.org/10.1016/j.critrevonc.2016.03.010
3. Grohé C (2019) Hyponatremia in oncology patients. Front Horm 52:161–166. https://doi.org/10.1159/000493245
4. Sørensen JB, Andersen MK, Hansen HH (1995) Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 238:97–110. https://doi.org/10.1111/j.1365-2796.1995.tb00907.x
5. Oronsky B, Caroen S, Oronsky A et al (2017) Electrolyte disturbances with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol 80:895–907. https://doi.org/10.1007/s00280-017-3392-8
6. Berardi R, Santoni M, Rinaldi S et al (2016) Risk of hyponatremia in cancer patients treated with targeted therapies: a systematic review and meta-analysis of clinical trials. PLoS One 11:e0152079. https://doi.org/10.1371/journal.pone.0152079
7. Wanchoo R, Karam S, Uppal NN et al (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45:160–169. https://doi.org/10.1159/000455014
8. Berardi R, Mastroianni C, Lo Russo G et al (2019) Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. Ther Adv Med Oncol 11:1758835919877725. https://doi.org/10.1177/1758835919877725
9. Hansen O, Sørensen P, Hansen KH (2010) The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 68:111–114. https://doi.org/10.1016/j.lungcan.2009.05.015
10. Kim HS, Yi SY, Jun HJ et al (2007) Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 73:192–197. https://doi.org/10.1159/0000127386
11. Corona G, Giuliani C, Parenti G et al (2013) Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS ONE 8:e80451. https://doi.org/10.1371/journal.pone.0080451
12. Holland-Bill L, Christiansen CF, Heide-Jørgensen U et al (2015) Hyponatremia and mortality risk: a Danish cohort study of 279 508 acutely hospitalized patients. Eur J Endocrinol 173:71–81. https://doi.org/10.1530/EJE-15-0111
13. Tiseo M, Buti S, Boni L et al (2014) Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan. Lung Cancer 86:91–95. https://doi.org/10.1016/j.lungcan.2014.07.022
14. Kobayashi N, Usui S, Yamaoka M et al (2014) The influence of serum sodium concentration on prognosis in resected non-small cell lung cancer. Thorac Cardiovasc Surg 62:338–343. https://doi.org/10.1056/0033-1359713
15. Berardi R, Caramanti M, Fiordoliva I et al (2015) Hyponatremia is a predictor of clinical outcome for malignant pleural mesothelioma. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 23:621–626. https://doi.org/10.1007/s00520-014-2398-6
16. Jeppesen AN, Jensen HK, Donskov F et al (2010) Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 102:867–872. https://doi.org/10.1038/sj.bjc.6605563
17. Farid SG, Prasad KR (2015) Prognostic impact of hyponatremia in patients with colorectal cancer. Color Dis Off J Assoc Coloproctol Gt Britain Irel 17:451
18. Fucà G, Mariani L, Lo Vullo S et al (2019) Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the hypnosis study. Sci Rep 9:12993. https://doi.org/10.1038/s41598-019-49601-3
19. Sengupta A, Banerjee SN, Biswas NM et al (2013) The incidence of hyponatremia and its effect on the ECOG performance status among lung cancer patients. J Clin Diagn Res 7:1678–1682. https://doi.org/10.7860/JCDR/2013/5900.3225
20. Berardi R, Caramanti M, Castagnani M et al (2015) Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 23:3095–3101. https://doi.org/10.1007/s12885-015-1156-6
21. Wald R, Jaber BL, Price LL et al (2010) Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 170:294–302. https://doi.org/10.1001/archinternmed.2009.513
22. Corona G, Giuliani C, Parenti G et al (2016) The economic burden of hyponatremia: systematic review and meta-analysis. Am J Med 129:823–835.e4. https://doi.org/10.1016/j.amjmed.2016.03.007
23. Balachandran K, Okines A, Gunapala R et al (2015) Resolution of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45:160–169. https://doi.org/10.1159/000455014
first-line therapy. Oncotarget 8:23871–23879. https://doi.org/10.18632/oncotarget.13372
25. Kasi PM (2012) Proposing the use of hyponatremia as a marker to help identify high risk individuals for lung cancer. Med Hypotheses 79:327–328. https://doi.org/10.1016/j.mehy.2012.05.023
26. Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD (2011) Mortality and serum sodium: do patients die from or with hyponatremia? Clin J Am Soc Nephrol 6:960–965. https://doi.org/10.2215/CJN.10111110
27. Marroncini G, Fabbri B, Errico A et al (2020) Effects of low extra-cellular sodium on proliferation and invasive activity of cancer cells in vitro. Endocrine 67:473–484. https://doi.org/10.1007/s12020-019-02135-0
28. Berl T, Quittnat-Pelletier F, Verbalis JG et al (2010) Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21:705–712. https://doi.org/10.1681/ASN2009080857
29. Peri A (2013) Clinical review: the use of vaptans in clinical endocrinology. J Clin Endocrinol Metab 98:1321–1332. https://doi.org/10.1210/jc.2012-4082
30. Greenberg A, Verbalis JG, Amin AN et al (2015) Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int 87:167–177. https://doi.org/10.1038/ki.2015.4
31. Bhandari S, Peri A, Cranston I et al (2017) A systematic review and meta-analysis of the prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 33:585–593. https://doi.org/10.3892/ijo_0000044
32. Castillo JJ, Vincent M, Justice E (2012) Diagnosis and management of hyponatremia in cancer patients. Oncologist 17:756–765. https://doi.org/10.1634/theoncologist.2011-0400
33. Berardi R, Antonuzzo A, Blasi L et al (2018) Practical issues for the management of hyponatremia in oncology. Endocrine 61:158–164. https://doi.org/10.1007/s12020-018-1547-y
34. Torres VE, Chapman AB, Devuyst O et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377:1930–1942. https://doi.org/10.1056/NEJMo11710030
35. Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407–2418. https://doi.org/10.1056/NEJMo1205511
36. Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323–1326. https://doi.org/10.1038/nm935
37. Wu Y, Beland FA, Chen S et al (2015) Mechanisms of tolvaptan-induced toxicity in HepG2 cells. Biochem Pharmacol 95:324–336. https://doi.org/10.1016/j.bcp.2015.03.015
38. Sinha S, Dwivedi N, Tao S et al (2020) Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene 39:1231–1245. https://doi.org/10.1038/s41388-019-1059-0
39. Marroncini G, Anceschi C, Naldi L et al (2021) Low sodium and tolvaptan have opposite effects in human small cell lung cancer cells. Mol Cell Endocrinol 537:111419. https://doi.org/10.1016/j.mce.2021.111419
40. Wang H, Zhao Y, Chen T et al (2019) MiR-371 promotes proliferation and metastasis in hepatocellular carcinoma by targeting PTEN. DMB Rep 52:312–317. https://doi.org/10.5483/DMBRep.2019.52.5.155
41. Cabrjan T, Skreb F, Suskovic T (1985) Syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) produced by an adenocarcinoma of the colon. Report of one case Endocrinologie 23:213–216
42. Eltawansy S, Gomez J, Liss K, et al (2015) Syndrome of inappropriate anti-diuretic hormone secondary to non-cirrhotic primary hepatocellular carcinoma. Am J Case Rep 16:31–36. https://doi.org/10.12659/AJCIR.892370
43. Nakano T, Motoshita J, Sawada F et al (2017) Syndrome of inappropriate antidiuretic hormone secretion in a case of olfactory neuroblastoma without anti-diuretic hormone immunoreactivity: A case report and review of the literature. Auris Nasus Larynx 44:771–774. https://doi.org/10.1016/j.anl.2016.11.012
44. Rodenburg WS, van Buul JD (2021) Rho GTPase signalling networks in cancer cell transendothelial migration. Vasc Biol (Bristol, England) 3:R77–R95. https://doi.org/10.1530/VB-21-0008
45. Dyberg C, Fransson S, Andonova T et al (2017) Rho-associated kinase is a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 114:E6603–E6612. https://doi.org/10.1073/pnas.1706111114
46. Kamai T, Tsujii T, Arai K et al (2003) Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res Off J Am Assoc Cancer Res 9:2632–2641
47. Zhang J, He X, Ma Y et al (2015) Overexpression of ROCK1 and ROCK2 inhibits human laryngeal squamous cell carcinoma. Int J Clin Exp Pathol 8:244–251
48. Lane J, Martin TA, Watkins G et al (2008) The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 33:585–593. https://doi.org/10.3892/ijo_0000044
49. Tanaka K, Matsumoto Y, Ishikawa H et al (2020) Impact of RhoA overexpression on clinical outcomes in cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. J Radiat Res 61:221–230. https://doi.org/10.1093/jrr/rzz093
50. Lou Z, Lin W, Zhao H et al (2021) Alkaline phosphatase down-regulation promotes lung adenocarcinoma metastasis via the c-Myc/RhoA axis. Cancer Cell Int 21:217. https://doi.org/10.1186/s12935-021-01919-7
51. Li MJ, Xiong D, Huang H, Wen ZY (2021) Ezrin promotes the proliferation, migration, and invasion of ovarian cancer cells. Biomed Environ Sci 34:139–151. https://doi.org/10.3967/bes2021.020.020
52. Kitai Y, Ishiura M, Saitoh K et al (2021) CD47 promotes T-cell lymphoma metastasis by up-regulating AKAP13-mediated RhoA activation. Int Immunol 33:273–280. https://doi.org/10.1093/intimm/dxia002
53. Xia Y, Cai X, Fan J et al (2017) RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro. Anticancer Drugs 28:514–521. https://doi.org/10.1097/CAD.0000000000000940
54. Xia Y, Cai X-Y, Fan J-Q et al (2017) RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of B16 mouse melanoma cells both in vitro and in vivo. Mol Cancer Ther 16:1582–1590. https://doi.org/10.1158/1535-7163.MCT-14-0523
55. Pollard TD, Borisy GG (2003) Cellular motility driven by assembly and disassembly of actin filaments. Cell 112:453–465. https://doi.org/10.1016/s0092-8674(03)00120-x
56. Negishi V (2014) Insights into the mechanism for dictating polarity in migrating T-cells. Int Rev Cell Mol Biol 312:201–270. https://doi.org/10.1016/B978-0-12-800178-3.00007-5
57. Shoaf SE, Kim SR, Bricmont P, Mallikaarjun S (2012) Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects. Eur J Clin Pharmacol 68:1595–1603. https://doi.org/10.1007/s00228-012-1298-5
58. Torres VE, Higashihara E, Devuyst O et al (2016) Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol 11:803–811. https://doi.org/10.2215/CINJ.06300615
59. Corona G, Giuliani C, Verbalis JG et al (2015) Hyponatremia improvement is associated with a reduced risk of mortality:
evidence from a meta-analysis. PLoS One 10:e0124105. https://doi.org/10.1371/journal.pone.0124105

60. Petereit C, Zaba O, Teber I, Grohé C (2011) Is hyponatremia a prognostic marker of survival for lung cancer? Pneumologie 65:565–571. https://doi.org/10.1055/s-0030-1256668

61. Berardi R, Rinaldi S, Santoni M, et al (2016) Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget 7:26916–26924. https://doi.org/10.18632/oncotarget.8309

62. Torres VE, Wang X, Qian Q et al (2004) Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10:363–364. https://doi.org/10.1038/nm1004

63. Wang X, Wu Y, Ward CJ et al (2008) Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19:102–108. https://doi.org/10.1681/ASN.2007060688

64. Keegan BP, Akerman BL, Péqueux C, North WG (2006) Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies. Breast Cancer Res Treat 95:265–277. https://doi.org/10.1007/s10549-005-9024-8

65. North WG (2000) Gene regulation of vasopressin and vasopressin receptors in cancer. Exp Physiol. https://doi.org/10.1111/j.1469-445x.2000.tb00005.x

66. MacKinnon AC, Tufail-Hanif U, Lucas CD et al (2005) Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition. Br J Cancer 92:522–531. https://doi.org/10.1038/sj.bjc.6602366

67. Péqueux C, Keegan BP, Hagelstein M-T et al (2004) Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer 11:871–885. https://doi.org/10.1677/erc.1.00803

68. Bolignano D, Medici MA, Coppolino G et al (2010) Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). Urol Oncol 28:642–647. https://doi.org/10.1016/j.urolonc.2008.12.014

69. Sinha VK, Ko B (2015) Hyponatremia in cirrhosis—pathogenesis, treatment, and prognostic significance. Adv Chronic Kidney Dis 22:361–367. https://doi.org/10.1053/j.ackd.2015.02.002

70. Wu R, Li C, Wang Z, et al (2020) A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia. Transl Lung Cancer Res 9:2469–2478. https://doi.org/10.21037/tlcr-20-1147

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.